Javier San - Mar 3, 2025 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Mark Worthington, Attorney-in-Fact for Javier San Martin
Stock symbol
ATHA
Transactions as of
Mar 3, 2025
Transactions value $
$0
Form type
4
Date filed
3/4/2025, 04:29 PM
Previous filing
Jan 3, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +111K $0.00 111K Mar 3, 2025 Common Stock 111K $0.38 Direct F1
transaction ATHA Restricted Stock Units Award $0 +74.2K $0.00 74.2K Mar 3, 2025 Common Stock 74.2K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F3 100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date.